Thermo Fisher Scientific Inc. $TMO Shares Sold by Parkside Financial Bank & Trust

Parkside Financial Bank & Trust trimmed its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 16.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 978 shares of the medical research company’s stock after selling 195 shares during the quarter. Parkside Financial Bank & Trust’s holdings in Thermo Fisher Scientific were worth $397,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. Nuveen LLC acquired a new stake in shares of Thermo Fisher Scientific during the first quarter worth about $532,360,000. EdgePoint Investment Group Inc. acquired a new stake in Thermo Fisher Scientific during the 1st quarter worth approximately $172,139,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Thermo Fisher Scientific by 13.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,750,923 shares of the medical research company’s stock valued at $1,368,859,000 after purchasing an additional 329,974 shares during the last quarter. Auto Owners Insurance Co increased its holdings in shares of Thermo Fisher Scientific by 6,773.5% in the first quarter. Auto Owners Insurance Co now owns 288,000 shares of the medical research company’s stock valued at $143,309,000 after purchasing an additional 283,810 shares during the period. Finally, Alliancebernstein L.P. lifted its holdings in shares of Thermo Fisher Scientific by 18.3% during the first quarter. Alliancebernstein L.P. now owns 1,766,067 shares of the medical research company’s stock worth $878,795,000 after purchasing an additional 272,747 shares during the period. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Up 1.2%

Thermo Fisher Scientific stock opened at $572.72 on Monday. The firm has a market capitalization of $215.18 billion, a price-to-earnings ratio of 33.09, a price-to-earnings-growth ratio of 3.27 and a beta of 0.82. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 1.50. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $610.97. The stock’s fifty day moving average is $518.58 and its two-hundred day moving average is $462.80.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, topping the consensus estimate of $5.50 by $0.29. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The business had revenue of $11.12 billion for the quarter, compared to analyst estimates of $10.90 billion. During the same period in the previous year, the firm earned $5.28 EPS. The business’s revenue for the quarter was up 4.9% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, January 15th. Stockholders of record on Monday, December 15th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend is Monday, December 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 9.94%.

Thermo Fisher Scientific declared that its board has authorized a share repurchase plan on Thursday, November 6th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical research company to reacquire up to 2.4% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s board of directors believes its stock is undervalued.

Wall Street Analyst Weigh In

Several brokerages have issued reports on TMO. Argus boosted their price objective on shares of Thermo Fisher Scientific from $580.00 to $610.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Cowen reiterated a “buy” rating on shares of Thermo Fisher Scientific in a research note on Thursday, October 23rd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Thermo Fisher Scientific in a report on Tuesday, October 14th. TD Cowen increased their target price on Thermo Fisher Scientific from $612.00 to $654.00 and gave the stock a “buy” rating in a research note on Thursday, October 23rd. Finally, Robert W. Baird upped their price objective on Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an “outperform” rating in a report on Thursday, July 24th. Nineteen investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $601.65.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 7,250 shares of the stock in a transaction on Monday, October 27th. The stock was sold at an average price of $566.10, for a total transaction of $4,104,225.00. Following the sale, the chief executive officer owned 113,762 shares in the company, valued at approximately $64,400,668.20. This represents a 5.99% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Gianluca Pettiti sold 400 shares of the company’s stock in a transaction on Friday, October 24th. The shares were sold at an average price of $574.15, for a total value of $229,660.00. Following the completion of the sale, the executive vice president owned 21,152 shares in the company, valued at $12,144,420.80. This represents a 1.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 36,420 shares of company stock valued at $19,980,884. 0.33% of the stock is owned by corporate insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.